Published in Lancet on December 12, 1998
FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging (2008) 1.00
Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin Exp Immunol (2002) 0.99
Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. J Clin Immunol (2003) 0.98
Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest (2015) 0.89
HIV-1 and IL-1β regulate astrocytic CD38 through mitogen-activated protein kinases and nuclear factor-κB signaling mechanisms. J Neuroinflammation (2011) 0.87
Overexpression of a novel lymphocyte population, positive for an intracellular CD14-like antigen, in patients positive for human immunodeficiency virus type 1. Clin Diagn Lab Immunol (2004) 0.78
The signaling protein CD38 is essential for early embryonic development. J Biol Chem (2012) 0.76
Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART. AIDS Res Ther (2011) 0.75
CD38/CD8 expression and HAART failure. Lancet (1999) 0.75
Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences. Cell (1981) 20.72
Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell (1986) 4.66
Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science (1994) 3.92
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 3.75
Glucocorticoid receptor mutants that are constitutive activators of transcriptional enhancement. Nature (1987) 3.42
Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 3.30
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med (1997) 3.22
The checkpoint protein Ddc2, functionally related to S. pombe Rad26, interacts with Mec1 and is regulated by Mec1-dependent phosphorylation in budding yeast. Genes Dev (2000) 2.82
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Functional dissection of the hormone and DNA binding activities of the glucocorticoid receptor. EMBO J (1987) 2.46
Transformation of frog embryos with a rabbit beta-globin gene. Proc Natl Acad Sci U S A (1981) 2.37
Metal binding 'finger' structures in the glucocorticoid receptor defined by site-directed mutagenesis. EMBO J (1988) 2.26
Eukaryotic expression vectors for the analysis of mutant proteins. Nucleic Acids Res (1989) 2.15
Transmission and expression of a specific pair of rearranged immunoglobulin mu and kappa genes in a transgenic mouse line. Nature (1985) 2.08
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood (2000) 1.94
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol (1996) 1.93
Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS (2000) 1.91
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS (1999) 1.89
Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis (1999) 1.88
Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS (1998) 1.86
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Hawking radiation from ultrashort laser pulse filaments. Phys Rev Lett (2010) 1.80
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today (1996) 1.75
Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol (2000) 1.69
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS (2000) 1.66
Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 1.65
Yeast Gpi8p is essential for GPI anchor attachment onto proteins. EMBO J (1996) 1.64
Selective enhancement of gene transfer by steroid-mediated gene delivery. Nat Biotechnol (2001) 1.63
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
Identification by polymerase chain reaction fingerprinting of Cryptococcus neoformans serotype AD. J Med Vet Mycol (1998) 1.57
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Characterization of mec1 kinase-deficient mutants and of new hypomorphic mec1 alleles impairing subsets of the DNA damage response pathway. Mol Cell Biol (2001) 1.53
A single DNA-binding transcription factor is sufficient for activation from a distant enhancer and/or from a promoter position. EMBO J (1990) 1.48
An unusual evolutionary behaviour of a sea urchin histone gene cluster. EMBO J (1982) 1.48
Cutaneous infection caused by Mycobacterium gordonae in a human immunodeficiency virus-infected patient receiving antimycobacterial treatment. Clin Infect Dis (1997) 1.46
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol (2001) 1.45
Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest (1991) 1.44
In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis (1996) 1.41
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection. J Pediatr (1999) 1.41
Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res (1996) 1.39
Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS (1996) 1.39
A strategy for prophylactic vaccination against HIV. Science (1993) 1.38
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS (1999) 1.36
Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis (1996) 1.36
CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol (1996) 1.35
Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann Hum Genet (1997) 1.34
Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS (1997) 1.32
Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology (2007) 1.32
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett (2001) 1.31
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol (2011) 1.30
Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling. BMC Cell Biol (2001) 1.28
CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol (2000) 1.28
Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment. J Biol Chem (1989) 1.28
An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.28
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol (1993) 1.25
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood (1996) 1.23
T-helper cell responses to HIV envelope peptides in cord blood: protection against intrapartum and breast-feeding transmission. AIDS (2001) 1.23
Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology (2004) 1.22
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost (2009) 1.19
JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects. Study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.19
Alpha complementation of LacZ in mammalian cells. Nucleic Acids Res (1996) 1.16
Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS (2001) 1.16
Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori (1982) 1.16
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther (2000) 1.16
Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol (1995) 1.11
Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis (2000) 1.09
PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging (2005) 1.09
The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. Mol Biol Cell (1998) 1.09
The PD-1/PD-L1 pathway in human pathology. Curr Mol Med (2012) 1.08
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS (2000) 1.07
Interference and synergism of glucocorticoid receptor and octamer factors. EMBO J (1991) 1.05
Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol (1994) 1.05
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect (2000) 1.04
Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis (1991) 1.04
Unusual malignant tumours in 49 patients with HIV infection. AIDS (1989) 1.04
Genetic correlates of protection against HIV infection: the ally within. J Intern Med (2009) 1.04
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol (2001) 1.04
Gluten-sensitive disease with mild enteropathy. Gastroenterology (1996) 1.03
Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol (1990) 1.03
Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression. J Pediatr (1995) 1.03
T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol (1993) 1.02
A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Endocrinology (1994) 1.01
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol (2011) 1.00
Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. J Immunol (1995) 1.00
Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS (1996) 0.99